Proposed changes to the vaccine approval system deserve the same scrutiny. Press reports indicate that new vaccines will be ...

Proposed changes to the vaccine approval system deserve the same scrutiny. Press reports indicate that new vaccines will be ...

Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.

Agents that target NaV1.8, a voltage-gated sodium channel, are showing promise. The FDA approved one of them, Journavx ...

Despite the main finding, there was one clear advantage: infants on caffeine were free from apnea about four days sooner than ...

Recently approved medications for resistant hypertension, uncomplicated UTIs and menopausal hot flashes show potential as ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. | Recursion is ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable clinical and endoscopic remission through 92 weeks in adults with moderately to ...

RFK Jr plans to change how vaccines are tested in the US, a decision that could impact how quickly and widely vaccines are made available.

Vitamin D supplementation during pregnancy was not associated with any effects on maternal bone mineral density at 4-year follow-up.

The FDA has approved Rinvoq (upadacitinib), a Janus kinase inhibitor, for the treatment of adults with giant cell arteritis.